Cumulative Rabbit Anti-human Thymocyte Globulin Dose to Recipient Weight During the Peri-operative Period is an Independent Risk Factor for Early Postoperative Urinary Tract Infection After Kidney Transplantation

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2024 Oct 16

PMID 39412045

Authors

Shujuan Li

Ziyu Wang

Zhen Dong

Yanwei Cao

Hongyang Wang

Affiliations

Soon will be listed here.

Abstract

Anti-human thymocyte globulin-Fresenius (ATG-F) is frequently utilized to achieve successful induction for kidney transplantation recipients. This study aimed to examine the association between the ATG-F dose-to-recipient-weight ratio (ADR) and the risk of developing urinary tract infections (UTIs) following kidney transplantation. Data of kidney transplant recipients who underwent ATG-F-induction peri-operatively in a medical center were retrospectively collected, and the incidence of UTIs during the first postoperative year was also recorded. The risk of UTI associated with ADR was analyzed, and receiver operating characteristic curves were drawn to determine the optimal ADR, followed by Cox regression models. In total, 131 recipients were included, with an UTI incidence of 19.08% and a mean interval of 3.08 months. The optimal ADR was 6.34, involving 41 and 90 patients in the low ADR and high ADR groups, respectively. The UTI-free rate in the low ADR group was significantly higher than that in the high ADR group ( = 0.007). Cox regression analysis indicated that a high ADR independently increased the risk of UTI following kidney transplantation (hazard ratio: 5.306, 95% confidence interval: 1.243-22.660, = 0.024). There was no significant difference in rejection rate between the high ADR and low ADR groups. In conclusion, a high ADR increased the incidence of early postoperative UTI among kidney transplant recipients.

References

Vilella P, Maldonado J, Fernandez P, Flores M, De Bernardi C, Vilte Velazquez K . [Clinical and microbiological characteristics of urinary tract infections in the first year after renal transplantation]. Rev Fac Cien Med Univ Nac Cordoba. 2023; 80(4):476-498. PMC: 10851398. DOI: 10.31053/1853.0605.v80.n4.41244. View

Couvrat-Desvergnes G, Salama A, Le Berre L, Evanno G, Viklicky O, Hruba P . Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival. J Clin Invest. 2015; 125(12):4655-65. PMC: 4665787. DOI: 10.1172/JCI82267. View

Goldman J, Julian K . Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33(9):e13507. DOI: 10.1111/ctr.13507. View

Padiyar A, Augustine J, Hricik D . Induction antibody therapy in kidney transplantation. Am J Kidney Dis. 2009; 54(5):935-44. DOI: 10.1053/j.ajkd.2009.06.020. View

Abou-Jaoude M, Almawi W . Intraoperative anti-thymocyte globulin-Fresenius (ATG-F) administration as induction immunosuppressive therapy in kidney transplantation. Mol Immunol. 2003; 39(17-18):1089-94. DOI: 10.1016/s0161-5890(03)00071-3. View

Kaden J, May G, Volp A, Wesslau C . Improved long-term survival after intra-operative single high-dose ATG-Fresenius induction in renal transplantation: a single centre experience. Ann Transplant. 2009; 14(3):7-17. View

Yin H, Xu Y, Zhang Q, Xue W, Zhang Z, Zeng S . [Safety and efficacy of preoperative induction therapy using a single high dose ATG-F in renal transplantation: a meta-analysis of randomized controlled trials]. Zhonghua Yi Xue Za Zhi. 2016; 96(22):1773-7. DOI: 10.3760/cma.j.issn.0376-2491.2016.22.013. View

Kaden J, Volp A, Wesslau C . High graft protection and low incidences of infections, malignancies and other adverse effects with intra-operative high dose ATG-induction: a single centre cohort study of 760 cases. Ann Transplant. 2013; 18:9-22. DOI: 10.12659/AOT.883792. View

Aydin S, Patil A, Desai M, Simforoosh N . Five compelling UTI questions after kidney transplant. World J Urol. 2020; 38(11):2733-2742. DOI: 10.1007/s00345-020-03173-4. View

10.

Charfeddine K, Kharrat M, Yaich S, Jarraya F, Mkawar K, Hachicha J . Infection in kidney transplant recipients in Tunisia. Saudi J Kidney Dis Transpl. 2007; 13(2):195-8. View

11.

Shimizu T, Sugihara T, Kamei J, Takeshima S, Kinoshita Y, Kubo T . Predictive factors and management of urinary tract infections after kidney transplantation: a retrospective cohort study. Clin Exp Nephrol. 2020; 25(2):200-206. DOI: 10.1007/s10157-020-01974-w. View

12.

Hill P, Cross N, Barnett A, Palmer S, Webster A . Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst Rev. 2017; 1:CD004759. PMC: 6464766. DOI: 10.1002/14651858.CD004759.pub2. View

13.

Urbanova M, Brabcova I, Girmanova E, Zelezny F, Viklicky O . Differential regulation of the nuclear factor-κB pathway by rabbit antithymocyte globulins in kidney transplantation. Transplantation. 2012; 93(6):589-96. DOI: 10.1097/TP.0b013e31824491aa. View

14.

Du X, Wang W, Sun Z, Su L, Zhang X . Meta-analysis on the Safety and Efficacy of the Reperfusion Use of a Single High Dose of Anti-T-Lymphocyte Globulin Fresenius in Kidney Transplantation. Transplant Proc. 2016; 48(6):2017-22. DOI: 10.1016/j.transproceed.2016.04.019. View

15.

Golebiewska J, Debska-Slizien A, Komarnicka J, Samet A, Rutkowski B . Urinary tract infections in renal transplant recipients. Transplant Proc. 2011; 43(8):2985-90. DOI: 10.1016/j.transproceed.2011.07.010. View

16.

Saemann M, Horl W . Urinary tract infection in renal transplant recipients. Eur J Clin Invest. 2008; 38 Suppl 2:58-65. DOI: 10.1111/j.1365-2362.2008.02014.x. View

17.

Bakr M, Nagib A, Donia A . Induction immunosuppressive therapy in kidney transplantation. Exp Clin Transplant. 2014; 12 Suppl 1:60-9. DOI: 10.6002/ect.25liver.l58. View

18.

Alangaden G, Thyagarajan R, Gruber S, Morawski K, Garnick J, El-Amm J . Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006; 20(4):401-9. DOI: 10.1111/j.1399-0012.2006.00519.x. View

19.

Shang W, Feng G, Gao S, Wang Z, Pang X, Li J . Reduced ATG-F dosage for induction in pediatric renal transplantation: a single-center experience. Pediatr Transplant. 2014; 18(3):240-5. DOI: 10.1111/petr.12224. View

20.

Pham C, Kuten S, Knight R, Nguyen D, Graviss E, Gaber A . Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab. Transpl Infect Dis. 2020; 22(3):e13257. DOI: 10.1111/tid.13257. View